Medical Molecular Morphology, published by SPRINGER JAPAN KK, stands as a significant resource in the fields of medicine and molecular biology, bridging critical insights between histological studies and modern therapeutic approaches. With an ISSN of 1860-1480 and E-ISSN of 1860-1499, this journal has evolved since its inception in 1996 and has continued to provide a platform for innovative research through 2024, establishing its relevance particularly in the realms of medical pathology and molecular morphology. Although categorized as Q3 in Medicine (miscellaneous) and Q4 in Molecular Biology per the 2023 quartiles, the journal's unique contributions cannot be understated, as evidenced by its Scopus rankings, which place it in the 52nd percentile for Pathology and 19th percentile for Molecular Biology. The journal’s mission focuses on disseminating valuable findings that enhance the understanding of cellular and molecular structures and their implications in health and disease. As access options are not currently open access, it remains essential for professionals and researchers to consider the journal's contributions as they pursue academic growth and impactful research in these dynamic fields.

Purinergic Signalling, published by Springer, is a pivotal academic journal dedicated to the exploration of purinergic signaling pathways and their implications in various biological processes. Since its inception in 2004, the journal has made significant contributions to the fields of Cell Biology, Cellular and Molecular Neuroscience, and Molecular Biology, consistently ranking in the Q3 category in recent assessments. With a strong focus on the molecular mechanisms of purines and their roles in physiology and pathology, Purinergic Signalling serves as an essential resource for researchers and professionals seeking to understand the complexity of cellular communication. Although it does not offer open access, the journal ensures a broad dissemination of high-quality research findings, making it a vital tool for academic advancement in the fields of neuroscience and molecular biology. Its commitment to scholarly excellence is reflected in its Scopus rankings, where it is competitively positioned within its categories. As we approach its 20th anniversary in 2024, Purinergic Signalling continues to inspire and inform cutting-edge research in the dynamic landscape of life sciences.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, published by Oxford University Press Inc, stands as a pivotal resource for advancing research and knowledge in the domains of neuropathology and experimental neurology. Established in 1942, this esteemed journal has expanded its influence, as evidenced by its Q1 rankings in both Neurology (clinical) and Pathology and Forensic Medicine, along with its strong placement in Cellular and Molecular Neuroscience. With an emphasis on innovative research and clinical practices, it caters to a diverse audience, including researchers and clinicians dedicated to understanding neurological disorders through a multidisciplinary lens. While not open access, this journal provides access to cutting-edge studies that are pivotal in shaping the future of medical science and pathology. Researchers benefit from its rigorous peer-review process, ensuring the publication of high-caliber work that meets the evolving demands of the field.

Fetal and Pediatric Pathology, an esteemed journal published by TAYLOR & FRANCIS INC, is dedicated to advancing the field of pediatric and fetal medicine through the dissemination of high-quality research and clinical insights. With an ISSN of 1551-3815 and an E-ISSN of 1551-3823, the journal has been a key resource for researchers and practitioners since its inception in 1983. Based in the United Kingdom, it covers a broad spectrum of topics relevant to Medicine, Pathology and Forensic Medicine, and Pediatrics, Perinatology, and Child Health, consistently reflecting on contemporary challenges faced in these fields. The journal has attained a commendable Q3 ranking within its categories as of 2023, underlining its relevance in the academic community. Though not an open-access publication, the research presented in Fetal and Pediatric Pathology plays a pivotal role in informing practice, guiding future studies, and enhancing the understanding of diseases affecting fetuses and children. Its convergence of research throughout multiple years, continuing until 2024, marks it as a crucial platform for ongoing scientific dialogue and innovation, aimed at fostering better health outcomes for younger populations.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

BRAIN PATHOLOGY, published by WILEY, is a leading journal in the fields of neurology, neuroscience, and pathology, recognized for its rigorous peer-review process and high-impact research contributions. With an impressive impact factor and consistently ranked in the Q1 quartile across multiple categories, BRAIN PATHOLOGY maintains a prominent status, with a Scopus ranking placing it among the top 10% of journals in its fields. Since its inception in 1990, the journal has served as a crucial platform for researchers and clinicians alike, disseminating groundbreaking findings that advance our understanding of brain diseases and injuries. Through its dedication to publishing high-quality, innovative research, BRAIN PATHOLOGY plays a vital role in shaping the future of brain pathology research. While it does not currently offer open access, articles can be accessed through institutional subscriptions. Researchers, professionals, and students are encouraged to contribute to and engage with this esteemed publication to foster knowledge and collaboration within this dynamic field.

CLINICAL NEUROPATHOLOGY is a vital scholarly journal published by DUSTRI-VERLAG DR KARL FEISTLE, specializing in the domains of neurology, pathology, and their clinical applications. Established in 1982 and spanning through to its projected completion in 2024, this journal disseminates high-quality research that significantly contributes to the understanding of neurological disorders and their pathological underpinnings. While the journal currently operates under a traditional access model, its commitment to rigorous peer review ensures the publication of impactful findings, strengthening its foothold in the field, as evidenced by its Q3 quartile rankings in several categories, including Medicine (miscellaneous), Neurology, and Pathology and Forensic Medicine. Those engaged in clinical research and practice will find CLINICAL NEUROPATHOLOGY to be an essential resource for the latest advancements, trends, and discussions that shape the future of neurological pathology.

ACTA NEUROBIOLOGIAE EXPERIMENTALIS, an esteemed journal published by the Nencki Institute of Experimental Biology in Poland, has been a pivotal platform for the dissemination of research in the fields of medicine and neuroscience since its inception in 1970. With an ISSN of 0065-1400 and an E-ISSN of 1689-0035, this journal has consistently aimed to contribute to the understanding of neurobiological phenomena, cementing its status within the academic community. Despite its current categorization in the Q3 and Q4 quartiles for Medicine and Neuroscience respectively, ACTA NEUROBIOLOGIAE EXPERIMENTALIS continues to uphold rigorous scientific standards, providing an invaluable resource for researchers, professionals, and students alike. As an essential scholarly outlet, it encourages the exploration of groundbreaking findings and clinical applications in neurobiology, making it an attractive choice for those eager to advance their understanding of this intricate field.

The INTERNATIONAL JOURNAL OF NEUROSCIENCE, published by TAYLOR & FRANCIS LTD, stands as a vital resource in the field of neuroscience since its inception. With a proud history of publication from 1970 to 2024, this journal is committed to advancing knowledge in various domains of neuroscience, from fundamental research to clinical applications. It is indexed with an ISSN of 0020-7454 and an E-ISSN of 1563-5279, reflecting its wide reach and recognition. The journal maintains a respectable position in the academic landscape, categorized as Q2 in Medicine (miscellaneous) and Q3 in Neuroscience (miscellaneous) as of 2023, signifying its relevance among researchers and professionals. Although it currently does not offer open access, the journal remains a significant platform for disseminating groundbreaking research, thereby fostering collaboration and innovation within the neuroscience community. Located in the United Kingdom, the journal aims to bridge gaps in neuroscience knowledge, making it an essential reading for students, professionals, and researchers dedicated to unraveling the complexities of the nervous system.